Drugs for Body Dysmorphic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 65)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Piracetam |
Approved, Investigational |
Phase 4 |
|
7491-74-9 |
|
2 |
|
Fluoxetine |
Approved, Vet_approved |
Phase 4 |
|
54910-89-3 |
3386
|
Synonyms:
(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+/-)-Fluoxetine
(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
52341-67-0
54910-89-3
57226-07-0
59333-67-4 (hydrochloride)
AB00053774
AC-14564
AC1L1FTH
Adofen
AKOS003663021
Animex-On
Bio-0787
Biomol-NT_000152
BPBio1_000354
BPBio1_000509
BRD-A31159102-001-01-9
BRD-A31159102-003-05-6
BSPBio_000461
BSPBio_003375
C17H18F3NO
CHEBI:5118
CHEMBL41
CID3386
D00326
DB00472
Deprex
DivK1c_006819
dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
Eufor
Floxetine
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
fluoxetine
Fluoxétine
fluoxetine (Prozac)
Fluoxetine (TN)
Fluoxetine (USAN/INN)
Fluoxetine [USAN:INN:BAN]
Fluoxetine Hcl
|
Fluoxetine hydrochloride
Fluoxetine Hydrochloride
Fluoxetinum
Fluoxetinum [INN-Latin]
Fluval
Fontex
Foxetin
HMS2090H14
KBio1_001763
KBio2_002159
KBio2_004727
KBio2_007295
KBio3_002595
KBioGR_001166
KBioSS_002159
L000931
Lilly-110140
Lopac0_000558
LS-31040
Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine
MolPort-001-683-482
NCGC00015428-10
NCGC00024879-03
NCGC00024879-04
nchembio.534-comp2
N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
NSC283480
Portal
Prestwick0_000511
Prestwick1_000511
Prestwick2_000511
Prestwick3_000511
Prozac
Prozac Weekly
Pulvules
Reconcile
Reneuron
Sarafem
SPBio_001815
SPBio_002382
SpecPlus_000723
Spectrum_001679
Spectrum2_001658
Spectrum3_001648
Spectrum4_000613
Spectrum5_001518
STK734483
Symbyax
TL8003595
UNII-01K63SUP8D
|
|
3 |
|
Norepinephrine |
Approved |
Phase 4 |
|
51-41-2 |
439260
|
Synonyms:
(-)-(R)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(-)-Arterenol
(-)-Arterenol free base
(-)-Noradrenaline
(-)-NORADRENALINE
(-)-Norepinephrine
(R)-(-)-Norepinephrine
(R)-4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-amino-1-Hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
Abbott brand OF levophed bitartrate
AC1L96ZT
Adrenor
Aktamin
ALBB-006229
Arterenol
Aventis brand OF norepinephrine hydrochloride
Bitartrate, levophed
Bitartrate, noradrenaline
Bitartrate, norepinephrine
bmse000404
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
DivK1c_000230
EINECS 200-096-6
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
Hydrochloride, norepinephrine
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-2-amino-1-(3,4-Dihydroxyphenyl)ethanol
L-3,4-dihydroxyphenylethanolamine
L-3,4-Dihydroxyphenylethanolamine
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-Arterenol
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
Levophed bitartrate
L-noradrenaline
|
L-Noradrenaline
L-Norepinephrine
L-NOREPINEPHRINE
LS-42676
LT03330026
LT4
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
noradrenaline
Noradrenaline
Nor-adrenaline
Noradrenaline (JP15)
Noradrenaline bitartrate
Noradrénaline tartrate renaudin
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
norepinefrina
Norepinefrina
Norepinephrin D-tartrate (1:1)
norepinephrine
Norepinephrine
Norepinephrine (INN)
Norepinephrine [INN:JAN]
Norepinephrine bitartrate
Norepinephrine D-tartrate (1:1)
Norepinephrine hydrochloride
Norepinephrine hydrochloride, (+)-isomer
Norepinephrine hydrochloride, (+,-)-isomer
Norepinephrine l-Tartrate (1:1)
Norepinephrine L-tartrate (1:1)
Norepinephrine L-tartrate (1:1), (+,-)-isomer
Norepinephrine L-tartrate (1:1), monohydrate
Norepinephrine L-tartrate (1:1), monohydrate, (+)-isomer
Norepinephrine L-tartrate (1:2)
Norepinephrine L-tartrate, (+)-isomer
Norepinephrine Noradrenalin
Norepinephrine, (+)-isomer
Norepinephrine, (+,-)-isomer
norepinephrinum
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
Nor-epirenan
PDSP1_001111
PDSP2_001095
Renaudin brand OF norepinephrine bitartrate
Renaudin, noradrénaline tartrate
SGCUT00123
SPBio_001048
Spectrum_001009
SPECTRUM1500436
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
STK503776
Sympathin e
Sympathin E
Tartrate renaudin, noradrénaline
to_000024
UNII-X4W3ENH1CV
|
|
4 |
|
Etiracetam |
Investigational |
Phase 4 |
|
33996-58-6 |
|
5 |
|
Nootropic Agents |
|
Phase 4 |
|
|
|
6 |
|
Neuroprotective Agents |
|
Phase 4 |
|
|
|
7 |
|
Anticonvulsants |
|
Phase 4 |
|
|
|
8 |
|
Protective Agents |
|
Phase 4,Phase 2 |
|
|
|
9 |
|
Serotonin Agents |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
10 |
|
Psychotropic Drugs |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
11 |
|
Neurotransmitter Uptake Inhibitors |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
12 |
|
Antidepressive Agents, Second-Generation |
|
Phase 4,Phase 3 |
|
|
|
13 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 4 |
|
|
|
14 |
|
Antidepressive Agents |
|
Phase 4,Phase 3 |
|
|
|
15 |
|
Serotonin Uptake Inhibitors |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
16 |
|
Neurotransmitter Agents |
|
Phase 4,Phase 3,Phase 2,Not Applicable |
|
|
|
17 |
|
Cytochrome P-450 CYP2D6 Inhibitors |
|
Phase 4 |
|
|
|
18 |
|
Serotonin and Noradrenaline Reuptake Inhibitors |
|
Phase 4 |
|
|
|
19 |
|
Venlafaxine Hydrochloride |
|
Phase 4 |
|
|
|
20 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 4,Phase 3,Phase 2 |
|
50-67-9 |
5202
|
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
Antemovis
|
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
Serotonine
sérotonine
thrombocytin
Thrombocytin
thrombotonin
Thrombotonin
|
|
21 |
|
Citalopram |
Approved |
Phase 3 |
|
59729-33-8 |
2771
|
Synonyms:
[3H]Citalopram
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
Bonitrile
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
C07572
C20H21FN2O
Celapram
Celexa
Celius
CHEBI:3723
CHEMBL549
Ciazil
CID2771
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
citalopram
Citalopram (USP/INN)
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopram Hydrobromide
Citalopramum
Citalopramum [INN-Latin]
Citol
|
Citopam
Citox
Citrol
CPD000465669
Cytalopram
D07704
Dalsan
DB00215
EINECS 261-891-1
Elopram
Escitalopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
Lexapro
Lopac0_000258
LS-84327
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
Seropram
ST069372
STL058639
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
|
|
22 |
|
Cholinergic Agents |
|
Phase 3 |
|
|
|
23 |
|
Parasympatholytics |
|
Phase 3 |
|
|
|
24 |
|
Cholinergic Antagonists |
|
Phase 3 |
|
|
|
25 |
|
Peripheral Nervous System Agents |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
26 |
|
Muscarinic Antagonists |
|
Phase 3 |
|
|
|
27 |
|
Autonomic Agents |
|
Phase 3,Phase 2 |
|
|
|
28 |
|
Antiparkinson Agents |
|
Phase 3,Not Applicable |
|
|
|
29 |
|
Oxytocin |
Approved, Vet_approved |
Phase 2 |
|
50-56-6 |
439302
53477758
|
Synonyms:
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
(Arg8)-vasopressin
(Arg8)-vasotocin
1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
50-56-6
AC1L9735
alpha-Hypophamine
Argipressin
Argpressin acetate
BCBcMAP01_000094
Biotinyl-(arg8)-vasopressin
C00746
CHEBI:492195
CHEBI:7872
CHEMBL395429
CID439302
Cys-tyr-ile-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-ile-GLN-asn-cys-pro-leu-gly-NH2
Cys-tyr-ile-THR-asn-cys-gly-leu-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-lys-gly-NH2
D00089
Disulfide bridge cys1-cys6
Gly-leu-pro-c
HS-2021
|
L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide
MolPort-003-938-941
NCGC00167132-01
nchembio.184-comp2
O3251_SIGMA
O4375_SIGMA
Ocytocin
Oxitocina
OXT
Oxytocic hormone
OXYTOCIN
Oxytocin (JP15/USP/INN)
Oxytocin (TN)
Oxytocin 10 usp units in dextrose 5%
Oxytocin 20 usp units in dextrose 5%
Oxytocin 5 usp units in dextrose 5%
Oxytocin acetate
Oxytocin injection
Oxytocine
Oxytocinum
Pitocin
Pitocin (TN)
Syntocinon
Syntocinon (TN)
TI-001
|
|
30 |
|
Milk thistle |
Approved, Experimental, Investigational |
Phase 2 |
|
65666-07-1 |
|
Synonyms:
822i9lej7s
Cardui Mariae Fructus
Carduus Marianus
Carduus Marianus Preparation
Carduus Marianus Seed
Fruit of Silybum Marianum
Holy Thistle Seed
Lady's Thistle Seed
Mariana Mariana Seed
Mary's Thistle Seed
Milk Thistle Extract
Milk Thistle Fruit
Milk Thistle Seed
Milk Thistle Seed Extract
|
Milk Thistle Silymarin
Milkthistle Fruit (Silybum Marianum L. Gaertner)
Saint Mary's Thistle Extract
Shuifeiji
Silybi Fructus
Silybi Mariani Fructus (Silybum Marianum L. Gaertner)
Silybum Marianum Dry Fruit
Silybum Marianum Dry Fruit Extract
Silybum Marianum Extract
Silybum Marianum Fruit
Silybum Marianum Fruit Extract
Silybum Marianum Seed
Silybum Marianum Seed Extract
|
|
31 |
|
Ondansetron |
Approved |
Phase 2 |
|
99614-02-5 |
4595
|
Synonyms:
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
99614-01-4 (mono-hydrochloride)
99614-02-5
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
AB00373674
AC1L1IIM
AKOS000599484
Apo-ondansetron
BAS 00717177
BPBio1_001118
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CBDivE_008994
CHEMBL46
CID4595
CPD001307702
D00456
DB00904
DESMETHYLONDANSETRON
Dihydrate, ondansetron monohydrochloride
GR 38032
GR 38032X
GR38032F
GR-38032F
HMS2090H16
Hydrochloride, ondansetron
I06-0687
I06-1329
L000456
LS-172305
LS-51878
|
MolPort-001-944-253
Monohydrochloride dihydrate, ondansetron
Monohydrochloride, ondansetron
NCI60_022780
Novo-ondansetron
ondansetron
Ondansetron (JAN/USP/INN)
ondansetron (Zofran)
Ondansetron [USAN:INN:BAN]
Ondansetron hydrochloride
Ondansetron monohydrochloride
Ondansetron monohydrochloride dihydrate
Ondansetron, (+,-)-isomer
Ondansetron, (+,-)-Isomer
Ondansetron, (R)-isomer
Ondansetron, (S)-isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
Ratio-ondansetron
SAM002589958
Sandoz ondansetron
SN-307
SPBio_002938
STK370548
STOCK4S-10990
TimTec1_001750
TL8006071
UNII-4AF302ESOS
Zofran
ZOFRAN IN PLASTIC CONTAINER
Zofran odt
Zofran ODT
Zofran ODT (TN)
Zophren
Zudan
|
|
32 |
|
Lactitol |
Investigational |
Phase 2 |
|
585-86-4 |
3871
|
Synonyms:
(2S,3R,4R,5R)-4-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}hexane-1,2,3,5,6-pentol
4-O-a-D-Glucopyranosyl-D-glucitol
4-O-alpha-delta-Glucopyranosyl-delta-glucitol
4-O-alpha-D-Glucopyranosyl-D-glucitol
4-O-α-D-glucopyranosyl-D-glucitol
a-D-GLC-(1->4)-D-GLC-ol
a-D-GLCP-(1->4)-D-GLC-ol
a-D-Glucosyl-(1->4)-D-glucitol
alpha-D-GLC-(1->4)-D-GLC-ol
alpha-D-GLCP-(1->4)-D-GLC-ol
alpha-D-Glucosyl-(1->4)-D-glucitol
Amalti syrup
Amalty MR 100
|
D-4-O-alpha-D-Glucopyranosylglucitol
delta-4-O-alpha-delta-Glucopyranosylglucitol
delta-Maltitol
D-Maltitol
lactitol
Malbit
Malti MR
Maltisorb
Maltit
α-D-GLC-(1->4)-D-GLC-ol
α-D-GLCP-(1->4)-D-GLC-ol
α-D-glucosyl-(1->4)-D-glucitol
|
|
33 |
|
Oxytocics |
|
Phase 2 |
|
|
|
34 |
|
Hormones |
|
Phase 2 |
|
|
|
35 |
|
Central Nervous System Depressants |
|
Phase 2,Not Applicable |
|
|
|
36 |
|
Antioxidants |
|
Phase 2 |
|
|
|
37 |
|
silymarin |
|
Phase 2 |
|
|
|
38 |
|
Serotonin Antagonists |
|
Phase 2 |
|
|
|
39 |
|
Tranquilizing Agents |
|
Phase 2 |
|
|
|
40 |
|
Anti-Anxiety Agents |
|
Phase 2 |
|
|
|
41 |
|
Dermatologic Agents |
|
Phase 2 |
|
|
|
42 |
|
Antipsychotic Agents |
|
Phase 2 |
|
|
|
43 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
44 |
|
Antipruritics |
|
Phase 2 |
|
|
|
45 |
|
Antiemetics |
|
Phase 2 |
|
|
|
46 |
|
Cycloserine |
Approved |
Early Phase 1 |
|
68-41-7 |
6234
401
|
Synonyms:
(+)-4-amino-3-Isoxazolidinone
(+)-4-Amino-3-isoxazolidinone
(+)-Cycloserine
(4R)-4-amino-1,2-oxazolidin-3-one
(4R)-4-Amino-3-isoxazolidinone
(4R)-4-aminoisoxazolidin-3-one
(R)-(+)-4-Amino-3-isoxazolidinone
(R)-(+)-Cycloserine
(R)-4-Amino-3-isoxazolidinone
(R)-4-Amino-3-isoxazolidone
(R)-4-amino-ISOXAZOLIDIN-3-one
(R)-4-AMINO-isoxazolidin-3-one
(R)-4-AMINO-ISOXAZOLIDIN-3-ONE
(R)-Cycloserine
1pb9
30020_FLUKA
30020_SIGMA
3-Isoxazolidinone, 4-amino-, (+)- (8CI)
3-Isoxazolidinone, 4-amino-, (4R)- (9CI)
3-Isoxazolidinone, 4-amino-, (R)
3-Isoxazolidinone, 4-amino-, D
4-27-00-05549 (Beilstein Handbook Reference)
4AX
68-41-7
AB00443920
AC1L1M33
AC1Q4UA7
AC-4721
a-Cycloserine
AI3-50153
alpha-Cycloserine
BB_NC-1631
BIDD:GT0707
BPBio1_001252
BRN 0080798
BSPBio_001138
BSPBio_002121
C 3909
C08057
C3909_SIGMA
C3H6N2O2
C6880_SIGMA
C7670_SIGMA
C-9390
C-9400
CAS-339-72-0
CAS-68-41-7
CHEBI:40009
CHEMBL771
Cicloserina
Cicloserina [INN-Spanish]
Cicloserina [Italian]
CID6234
Closerin
Closina
CPD000058313
CPD-2482
cyclo-D-Serine
Cyclo-D-serine
Cyclorin
cycloserine
Cycloserine
Cycloserine (JP15/USP/INN)
Cycloserine [INN:BAN:JAN]
Cycloserinum
Cycloserinum [INN-Latin]
D-(+)-Cycloserine
D00877
D-4-Amino-3-isossazolidone
D-4-Amino-3-isossazolidone [Italian]
D-4-amino-3-isoxazolidinone
D-4-amino-3-Isoxazolidinone
D-4-amino-3-isoxazolidone
D-4-amino-3-Isoxazolidone
D-amino-3-isoxazolidinone
DB03123
DCS
D-CS
D-cycloserine
D-Cycloserine
D-Cycloserine synth. BP 88
D-Cycloserine, synthetic
DivK1c_000098
DL-Cycloserine
D-Oxamicina
D-Oxamycin
DRG-0195
|
E-733-A
EINECS 200-688-4
EU-0100252
FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09
Farmiserina
HMS1571I20
HMS1920C06
HMS2051C15
HMS2091I14
HMS500E20
HSDB 3218
I-1431
IDI1_000098
K-300
KBio1_000098
KBio2_001340
KBio2_003908
KBio2_006476
KBio3_001341
KBioGR_000890
KBioSS_001340
L-Cycloserine
LMPK14000007
Lopac0_000252
Lopac-C-1159
Lopac-C-3909
Lopac-C-7005
LS-86757
Micoserina
Miroserina
Miroseryn
MLS000758215
MLS001423962
MolPort-000-858-643
NCGC00015213-01
NCGC00015213-02
NCGC00015213-03
NCGC00016306-01
NCGC00016306-02
NCGC00016306-03
NCGC00016306-05
NCGC00093713-01
NCGC00093713-02
NINDS_000098
Novoserin
NSC 154851
orientomycin
Orientomycin
Oxamicina
Oxamicina [Italian]
Oxamycin
PA 94
PA-94
Prestwick0_001089
Prestwick1_001089
Prestwick2_001089
Prestwick3_001089
R(+)-4-Amino-3-isoxazolidinone
R-(+)-Cycloserine
R-4-amino-3-Isoxazolidinone
R-4-Amino-3-isoxazolidinone
ro-1-9213
Ro-1-9213
RO-1-9213
S1998_Selleck
SAM001247014
SAM002264599
SC-49088
Seromycin
Seromycin (TN)
SMP1_000167
SMR000058313
SPBio_000008
SPBio_003029
Spectrum_000860
SPECTRUM1500215
Spectrum2_000084
Spectrum3_000371
Spectrum4_000305
Spectrum5_000797
Tebemicina
Tisomycin
UNII-95IK5KI84Z
Wasserina
α-cycloserine
α-Cycloserine
|
|
47 |
|
Dopamine |
Approved |
Not Applicable |
|
51-61-6, 62-31-7 |
681
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
48 |
|
Memantine |
Approved, Investigational |
Not Applicable |
|
19982-08-2 |
4054
|
Synonyms:
1,3-Dimethyl-5-adamantanamine
1,3-Dimethyl-5-aminoadamantane
19982-08-2
1-amino-3,5-Dimethyladamantane
1-Amino-3,5-dimethyladamantane
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-dimethyladamantan-1-amine
3,5-Dimethyladamantan-1-ylamine
3,5-dimethyltricyclo(3.3.1.1(3,7))Decan-1-amine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
Axura
BBL000737
Biomol-NT_000209
BPBio1_001117
BPBio1_001270
BSPBio_001015
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DivK1c_000068
DMAA
Ebixa
EU-0053634
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
|
KBio2_006223
KBio3_001926
KBioGR_001543
KBioSS_001087
Lopac0_000861
LS-157051
Lundbeck brand OF memantine hydrochloride
Memantin
Memantina
Memantina [INN-Spanish]
memantine
Memantine
Memantine (INN)
Memantine [INN:BAN]
Memantine [INN]
Memantine HCL
Memantine hydrochloride
Memantine Hydrochloride
Memantinum
Memantinum [INN-Latin]
Merz brand OF memantine hydrochloride
MolPort-002-041-858
Namenda
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
Spectrum_000607
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
ST057652
STK520682
UNII-W8O17SJF3T
ZERO/006024
|
|
49 |
|
Cocaine |
Approved, Illicit |
Not Applicable |
|
50-36-2 |
5760
446220
|
Synonyms:
(−)-cocaine
(-)-Cocaine
(-)-Cocaine base
(1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate
(1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate
(R)-Cocaine
[1R-(exo,exo)]-3-(Benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate, methyl ester
[1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, methyl ester
[1R-(exo,exo)]-3-(Benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, methyl ester
1-Cocaine
1i7z
1q72
2beta-Carbomethoxy-3beta-benzoxytropane
2-beta-Carbomethoxy-3-beta-benzoxytropane
2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester)
2-Methyl-3beta-hydroxy-1alphah,5alphah-tropane-2beta-carboxylate benzoate (ester)
2-Methyl-3beta-hydroxy-1alphah,5alphah-tropane-2beta-carboxylic acid benzoic acid (ester)
2-Methyl-3b-hydroxy-1alphah,5alphah-tropane-2b-carboxylate benzoate (ester)
2-Methyl-3b-hydroxy-1alphah,5alphah-tropane-2b-carboxylic acid benzoic acid (ester)
2-Methyl-3β-hydroxy-1alphah,5alphah-tropane-2β-carboxylate benzoate (ester)
2-Methyl-3β-hydroxy-1alphah,5alphah-tropane-2β-carboxylic acid benzoic acid (ester)
2-methyl-3β-hydroxy-1αH,5αH-tropane-2β-carboxylate benzoate (ester)
3beta-Hydroxy-2beta-tropanecarboxylic acid methyl ester benzoate (ester)
3-Tropanylbenzoate-2-carboxylic acid methyl ester
50-36-2
53-21-4 (hydrochloride)
610089_ALDRICH
610089_FLUKA
AC-16037
AC1L1EK2
AC1L1L2T
AC1L3U2D
AC1L9JBL
AC-20208
Allococaine
Allopseudococaine
Badrock
Bazooka
b-Cocain
Benzoylethylecgonine
Benzoylmethylecgonine
Bernice
Bernice [Street Name]
Bernies
beta-Cocain
Beta-Cocain
Blast
Blizzard
Blow
Blow [Street Name]
Bouncing Powder
Bump
Burese
C" Carrie
C01416
C8912_SIGMA
Cabello
Candy
Carrie
Caviar
Cecil
Cecil [Street Name]
Charlie
CHEBI:27958
Chicken Scratch
Cholly
CID11779748
CID2826
CID446220
CID5760
COC
Coca
Cocain
Cocaina
cocaine
Cocaine
Cocaine (TN)
Cocaine (USP)
Cocaine [BAN]
Cocaine free base
Cocaine Free Base
Cocaine HCL
Cocaine hydrochloride
Cocaine solution
Cocaine-M
cocainum
Cocainum
Cocktail
Coke
Cola
Corine
CPD-9776
Crack
Crack cocaine
D00110
Dama blanca
Dama Blanca
DB00907
DEA No. 9041
Delcaine
Depsococaine
Dextrocaine
DivK1c_000975
|
d-Pseudococaine
D-pseudococaine
Dust
Ecgonine methyl ester benzoate
Ecgonine methyl ester benzoate solution
Ecgonine, methyl ester, benzoate (ester)
EINECS 200-032-7
Eritroxilina
Erytroxylin
Flake
Flake [Street Name]
Flex
Florida Snow
Foo Foo
Freeze
Girl
Girl [Street Name]
Gold dust
Gold Dust
Gold dust [Street Name]
Goofball
Green gold
Green Gold
G-Rock
Happy dust
Happy Dust
Happy dust [Street Name]
Happy powder
Happy Powder
Happy trails
Happy Trails
HCL, Cocaine
Heaven
Hell
HSDB 6469
Hydrochloride, cocaine
IDI1_000975
Isocaine
Isococain
Isococaine
Jam
KBio1_000975
Kibbles n' Bits
Kibbles N' Bits
Kokain
Kokan
Kokayeen
L000836
Lady
Lady [Street Name]
l-Cocain
L-Cocain
L-Cocaine
Leaf
LS-157759
methyl (1S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate
methyl (3S,4R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate
methyl [1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
Methyl [1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
Methyl [1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid
Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate
Methyl 3beta-hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylate benzoate (ester)
Methyl benzoylecgonine
Methyl Benzoylecgonine
MLS002320697
MolPort-002-535-520
MolPort-003-937-722
Moonrocks
NCGC00159467-02
nchembio.284-comp4
Neurocaine
NINDS_000975
Nose candy
Pimp's drug
Pimp's Drug
Prime Time
Pseudoallococaine
Pseudococaine
Rock
Rock [Street Name]
Sleighride
SMR001338843
Snort
Snow
Snow (birds)
Star dust
Star Dust
Star-spangled powder
Star-Spangled Powder
STOCK1N-68258
Sugar
Sweet Stuff
Toke
Toot
Toot [Street Name]
Trails
UNII-I5Y540LHVR
White girl or lady
Yeyo
Zip
β-cocain
|
|
50 |
|
Diprenorphine |
Illicit, Vet_approved |
Not Applicable |
|
14357-78-9 |
|
Synonyms:
|
Interventional clinical trials:
(show all 38)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder |
Completed |
NCT00265109
|
Phase 4 |
Levetiracetam |
2 |
Fluoxetine in Pediatric Body Dysmorphic Disorder |
Completed |
NCT00245635
|
Phase 4 |
Fluoxetine;Placebo |
3 |
CBT as an Adjunct to SRIs in the Treatment of BDD |
Terminated |
NCT00211809
|
Phase 4 |
Venlafaxine |
4 |
Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder |
Completed |
NCT00149799
|
Phase 3 |
Escitalopram;Placebo |
5 |
Study of Patients With Body Image Issues Treated With 2 Different Behavioral Interventions |
Unknown status |
NCT01316627
|
Phase 2 |
|
6 |
Oxytocin Administration in BDD and OCD |
Completed |
NCT02671266
|
Phase 2 |
Oxytocin;Placebo |
7 |
Milk Thistle in Body Dysmorphic Disorder |
Recruiting |
NCT02843451
|
Phase 2 |
Milk Thistle;Placebo |
8 |
Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder |
Terminated |
NCT01275248
|
Phase 2 |
Ondansetron;Placebo |
9 |
Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder |
Unknown status |
NCT01453439
|
Not Applicable |
|
10 |
Body Image and Self-Care in HIV-Infected MSM |
Unknown status |
NCT01817621
|
Not Applicable |
|
11 |
Interpretation Bias Modification for Body Dysmorphic Disorder |
Completed |
NCT02635152
|
Not Applicable |
|
12 |
Attentional Bias in Body Dysmorphic Disorder |
Completed |
NCT01398904
|
|
|
13 |
Internet Cognitive Behavior Therapy (CBT) for Body Dysmorphic Disorder (BDD) |
Completed |
NCT01850433
|
Not Applicable |
|
14 |
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder |
Completed |
NCT00842309
|
Early Phase 1 |
d-cycloserine;Placebo |
15 |
Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder |
Completed |
NCT00106223
|
Not Applicable |
|
16 |
Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder |
Completed |
NCT01002326
|
Not Applicable |
|
17 |
Internet Delivered CBT for Body Dysmorphic Disorder |
Completed |
NCT02010619
|
Not Applicable |
|
18 |
An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder |
Completed |
NCT01038128
|
Not Applicable |
Memantine |
19 |
Prevention of Body Image Disorder by Nurse Intervention on the Patient and Family Prior to Breast and Colon Surgery |
Completed |
NCT03726801
|
Not Applicable |
|
20 |
Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD) |
Completed |
NCT00871143
|
Not Applicable |
|
21 |
Escitalopram Neuroimaging Supplement |
Completed |
NCT01398865
|
|
|
22 |
Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study |
Completed |
NCT02524301
|
Not Applicable |
Positron Emission Tomography using [11C]diprenorphine |
23 |
Assessment of Body Image in Patients With Rheumatoid Arthritis |
Completed |
NCT00832910
|
|
|
24 |
Effectiveness of Dance on Patients With Fibromyalgia |
Completed |
NCT00961805
|
Not Applicable |
|
25 |
Impairment of Central Coherence in Restrictive Anorexia Nervosa (CoCA) |
Completed |
NCT02381639
|
Not Applicable |
|
26 |
Cortical Excitability in Obsessive-Compulsive and Related Disorders |
Completed |
NCT00029068
|
|
|
27 |
Contribution of a Virtual Reality Program in the Treatment of Dysmorphophobia for Adolescent Female With Anorexia Nervosa |
Recruiting |
NCT03426930
|
Not Applicable |
|
28 |
Body Image Disorder in Anorexia Nervosa and Virtual Reality |
Recruiting |
NCT03118921
|
Not Applicable |
|
29 |
Brain Correlates of Self-Focused Processing |
Recruiting |
NCT02808702
|
Not Applicable |
|
30 |
White Light Scanning to Aid Body Contouring: A Pilot Project |
Recruiting |
NCT01093950
|
|
|
31 |
The Pride Body Project |
Recruiting |
NCT03451513
|
Not Applicable |
|
32 |
Feasibility Pilot Study of Internet-based Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder With Global Recruitment |
Active, not recruiting |
NCT03517384
|
Not Applicable |
|
33 |
Smartphone-Administered App Treatment for Adults With Body Dysmorphic Disorder |
Active, not recruiting |
NCT03221738
|
Not Applicable |
|
34 |
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals |
Active, not recruiting |
NCT01075672
|
Not Applicable |
|
35 |
A Virtual Reality Study of Cognitive Biases in Body Dysmorphic Disorder |
Not yet recruiting |
NCT03773549
|
|
|
36 |
Waitlist-Control Trial of Smartphone CBT for Body Dysmorphic Disorder (BDD) |
Not yet recruiting |
NCT03673046
|
Not Applicable |
|
37 |
Effects of Mindfulness Meditation on Rhinoplasty Outcomes |
Not yet recruiting |
NCT03727815
|
Not Applicable |
|
38 |
Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders |
Withdrawn |
NCT01953042
|
Not Applicable |
|
|